ESTRO 2024 - Abstract Book

S736

Clinical - CNS

ESTRO 2024

39

Digital Poster

A single-center survey of 800 patients with newly diagnosed brain metastases from 2016 to 2021

Yutaro Koide, Naoya Nagai, Yurika Shindo, Tomoki Kitagawa, Takahiro Aoyama, Hidetoshi Shimizu, Shingo Hashimoto, Hiroyuki Tachibana, Takeshi Kodaira

Aichi Cancer Center Hospital, Radiation Oncology, Aichi, Japan

Purpose/Objective:

This study aimed to evaluate recent trends in characteristics and treatments among patients with brain metastases (BM) in clinical practice.

Material/Methods:

All newly diagnosed patients with BM during 2016 – 2021 at a single cancer center were enrolled. We collected the detailed features of each patient and estimated the number of candidates considered to meet the following criteria generally used in past clinical trials: KPS≥70 and mutated non -small cell lung cancer, breast cancer, or melanoma. The BM treatments were classified as follows: (1) stereotactic radiosurgery (SRS), (2) SRS and systemic therapy (ST), (3) whole-brain radiotherapy (WBRT), (4) WBRT and ST, (5) surgery, (6) immune checkpoint inhibitor (ICI) or targeted therapy, (7) cytotoxic agents, and (8) palliative care. Overall survival (OS) and intracranial progression-free survival (PFS) were estimated from BM diagnosis to death or intracranial progression.

Results:

A total of 800 BM patients were analyzed; 597 (74.6%) underwent radiotherapy, and 422 (52.7%) underwent ST. In addition, 250 (31.3%) patients were considered candidates for common clinical trials. Compared to 2016, the later years tended to shift from WBRT to SRS (WBRT: 35.7% to 29.1%, SRS: 33.4% to 42.8%) and from cytotoxic agents to ICI/targeted therapy (cytotoxic agents: 10.1% to 5.0%, ICI/targeted therapy: 7.8% to 10.9%). There was also an increase in the proportion of ST combined with RT (from 26.4% to 36.5%). The median OS and PFS were 12.7 months and 5.3 months, respectively.

Conclusion:

The result of this study revealed the diversity of BM patient characteristics, recent changes in treatment selection, and the percentage of candidates in clinical trials.

Keywords: brain metastases, radiotherapy, radiosurgery